Roche to Acquire Promedior for $1.39B

 Roche to Acquire Promedior for $1.39B

Roche to Acquire Promedior for $1.39B

Shots:

  • Promedior to receive $390M up front and up to $1B development, regulatory and commercial milestones, making the total deal value as $1.39B. Roche to get full rights for Promedior’s fibrotic diseases portfolio including its lead asset PRM-151
  • The acquisition will leverage Roche’s drug development capabilities and expertise to further advance PRM-151 in fibrotic diseases, including idiopathic pulmonary fibrosis and myelofibrosis
  • Promedior’s PRM-151 is a recombinant form of human pentraxin-2 (PTX-2) protein, demonstrated both prevention and reversal of fibrosis and has received FDA’s breakthrough therapy designation for IPF in H1’19

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Promedior

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post